S&P DJI Announces September 2023 Quarterly Rebalance
Filed with ASX · · 4 pages · English
Story so far
Earlier from Imugene
- Preliminary Final Report
- Imugene completes $35M Placement & Launches c.$30M SPP
- Imugene Licenses Allogeneic CD19 CAR T Cell Therapy
- Imugene VAXINIA Trial clears Cohort 3 of IT Monotherapy
- Imugene CF33 Oncolytic Virus Study to be Showcased at SITC
Later from Imugene
- VAXINIA MAST Trial Clears Intratumoral Combination Cohort 1
- Imugene Receives Positive Feedback From FDA
- Imugene PD1-Vaxx Update
- Imugene Closes SPP Raising $18.2 million
- Azer-cel FDA IND Transferred to Imugene
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene